Year None202320222021202020192018 Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights Nov 07, 2023 Read More Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting Nov 03, 2023 Read More Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer Nov 01, 2023 Read More Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting Oct 25, 2023 Read More Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023 Oct 23, 2023 Read More Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo® Sep 27, 2023 Read More Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference Sep 21, 2023 Read More Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno Sep 13, 2023 Read More Sensei Biotherapeutics to Participate in Upcoming Investor Conferences Aug 30, 2023 Read More Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Aug 03, 2023 Read More Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 29
